CN110812374A - 治疗中风后遗症、帕金森及老年痴呆的膏剂及制备方法 - Google Patents
治疗中风后遗症、帕金森及老年痴呆的膏剂及制备方法 Download PDFInfo
- Publication number
- CN110812374A CN110812374A CN201810913371.7A CN201810913371A CN110812374A CN 110812374 A CN110812374 A CN 110812374A CN 201810913371 A CN201810913371 A CN 201810913371A CN 110812374 A CN110812374 A CN 110812374A
- Authority
- CN
- China
- Prior art keywords
- mixing
- far infrared
- disease
- ointment
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 20
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 11
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 9
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 8
- 208000006011 Stroke Diseases 0.000 title claims abstract description 8
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 239000000919 ceramic Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 15
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004831 Hot glue Substances 0.000 claims abstract description 14
- 229960003639 laurocapram Drugs 0.000 claims abstract description 14
- 240000004274 Sarcandra glabra Species 0.000 claims abstract description 13
- 235000010842 Sarcandra glabra Nutrition 0.000 claims abstract description 13
- 239000004744 fabric Substances 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 239000004753 textile Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 7
- 210000004556 brain Anatomy 0.000 abstract description 5
- 206010016256 fatigue Diseases 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 206010021143 Hypoxia Diseases 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 4
- 238000001467 acupuncture Methods 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 210000004958 brain cell Anatomy 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 208000006083 Hypokinesia Diseases 0.000 abstract description 2
- 208000032140 Sleepiness Diseases 0.000 abstract description 2
- 206010041349 Somnolence Diseases 0.000 abstract description 2
- 210000004204 blood vessel Anatomy 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 231100000241 scar Toxicity 0.000 abstract description 2
- 230000037321 sleepiness Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000000554 physical therapy Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 244000292604 Salvia columbariae Species 0.000 description 3
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 3
- 235000001498 Salvia hispanica Nutrition 0.000 description 3
- 201000004810 Vascular dementia Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000014167 chia Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- VARQGBHBYZTYLJ-UHFFFAOYSA-N tricosan-12-one Chemical compound CCCCCCCCCCCC(=O)CCCCCCCCCCC VARQGBHBYZTYLJ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0625—Warming the body, e.g. hyperthermia treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Hospice & Palliative Care (AREA)
- Alternative & Traditional Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种治疗中风后遗症、帕金森及老年痴呆的膏剂及制备方法;原料按重量百分比组成:草珊瑚提取物20%、远红外陶瓷粉30%、热熔胶30%、月桂氮酮20%;其制备方法,包括如下步骤:(1)草珊瑚提取物与月桂氮酮混合均匀,加入热熔胶;加热搅拌,制成稠浸膏状;(2)按比例混入远红外陶瓷粉;混合均匀;得到混合药膏;(3)与纺织布制成2.5cm×2.5cm或5cm×8cm厚为0.5cm的圆形药膏贴。本发明在体表经络部位有关穴位上用药,整个过程治疗安全,无痛苦,无瘢痕,标本兼治,无任何副作用。实现调虚实、保证传导功能、提高免疫能力;颈部的血管负责加速血液上注脑,让因缺氧的脑细胞迅速恢复原状,解决脑缺氧导致犯困、疲倦、乏力;同时让病理产物得到清除。
Description
技术领域
本发明属于中医药技术领域。具体涉及一种治疗中风后遗症、帕金森及老年痴呆的膏剂。
背景技术
现代医学认为,老年痴呆症系指发生在老年期的各种痴呆综合症,包括阿尔茨海默病(又称早老性痴呆,Alzheimer’s disease,AD)、血管性痴呆(Vascular dementia,D)、混合性痴呆。以脑的退行性病变,脑细胞萎缩为其病理基础的痴呆症候群。而AD多由缺血性、出血性脑病理引发,症状及神经生物化学特点往往相互交错重叠,人们曾做了许多工作去鉴别AD及VD,但随着研究的不断深入,两者间的相似性及两者可能在本质上的重叠性越来越受到人们重视。它们在临床上均表现为因认知功能减退所致记忆力下降,行为迟缓、动作不协调。
随着现代医学的不断发展,出现了一些药品,虽解除了许多患者的疾患,但多数临床医生及患者仍感到见效慢、疗效差、服药时间长、费用高、治疗面单一,与该病相关的症状和体征不能兼顾治疗。因此,发开发具有中医特色的防治血管性痴呆的膏剂,不仅可以弥补现代医学治疗上的不足,发挥中医中药的优势,而且适宜人群广、市场需求大、具有广阔的市场前景。
发明内容
针对现有技术中的不足之处,本发明提供一种治疗中风后遗症、帕金森及老年痴呆的膏剂及制备方法。
为了上述目的,本发明技术方案如下:
治疗中风后遗症、帕金森及老年痴呆的膏剂,原料按重量百分比组成:
草珊瑚提取物20%、远红外陶瓷粉30%、热熔胶30%、月桂氮酮20%。
上述治疗中风后遗症、帕金森及老年痴呆的膏剂的制备方法,包括如下步骤:
(1)草珊瑚提取物与月桂氮酮混合均匀,加入热熔胶;加热搅拌,制成稠浸膏状;
(2)按比例混入远红外陶瓷粉;混合均匀;得到混合药膏;
(3)与纺织布制成2.5cm×2.5cm或5cm×gcm厚为0.5cm的圆形药膏贴。
为了便于理解本发明,下面对本发明中的原料及药效作进一步阐述。
(1)草珊瑚:涩,凉;调和气血,止痛;治神经性头痛。根据广西大学对草珊瑚研究资料显示:含锌、硒、铜、锰、铁等微量元素以及16种氨基酸;功效:抗菌抗病毒、抗肿瘤,增强免疫力,抗胃溃疡,促进骨折愈合,鎭痛,抗疲劳,抗寒等作用;药理广乏,不良反应小;动物试验属无毒。
(2)远红外陶瓷粉:相当于起到理疗作用,其中的热能对细胞影响非常重要,在加快血液循环起到很好的作用;要对温度的控制到最适合,以较低温才能持久浸透里层组织。
①远红外辐射可以改善血液循环:因为远红外线能够深入人体的皮下组织,所以利用远红外线反应,使皮下深层皮肤温度上升,扩张微血管,促进血液循环,复活酵素,强化血液及细胞组织代谢,对细胞恢复年轻有很大的帮助并能改善贫血。调节血压:高血压及动脉硬化一般是神经系统、内分泌系统,肾脏等细小动脉收缩及狭窄所造成;远红外线扩张微血管,促进血液循环能使高血压降低,又能改善低血压症状。
②远红外辐射可以改善关节疼痛:远红外线深透力可达肌肉关节深处,使身体内部温暖,放松肌肉,带动微血管网的氧气及养分交换,并排除积存体内的疲劳物质和乳酸等老化废物对消除内肿,缓和酸痛之效果卓越。
③远红外辐射可以调节自律神经:自律神经主要是调节内脏功能,人长期处在焦虑状态,自律神经系统持续紧张,会导致免疫力降低,头痛,目眩,失眠乏力,四肢冰冷;远红外线可调节自律神经保持在最佳状态,以上症状均可改善或祛除。
④远红外辐射可以护肤美容:远红外线照射人体产生共鸣吸收,能将引起疲劳及老化的物质,如乳酸、游离脂肪酸、胆固醇、多余的皮下脂肪等,籍毛囊口和皮下脂肪的活化性,不经肾脏,直接从皮肤代谢。因此,能使肌肤光滑柔嫩;远红外线的理疗效果能使体内热能提高,细胞活化,因此促进脂肪组织代谢,燃烧分解,将多余脂肪消耗掉,进而有效减肥。
⑤远红外辐射可以改善循环系统:远红外线照射的全面性和深透性,对于遍布全身内外无以数计的微循环组织系统,是唯一能完全照顾的理疗方式;微循环顺畅之后,心脏收缩压力减轻,氧气和养分供应充足,自然身轻体健;强化肝脏功能:肝脏是体内最大的化学工厂,是血液的净化器;远红外线照射引起的体内热深层效应,能活化细胞,提高组织再生能力,促进细胞生长,强化肝脏功能,提高肝脏解毒、排毒作用,使内脏环境保持良好状态,可说是最佳的防病战略。
(3)丙烯酸压敏胶:水气透过性、吸水性,反复揭贴性等优点。
(4)月桂氮酮:皮肤渗透促进剂,能改变皮肤色质层脂质蛋白结构,促进药物对皮肤吸收。
所述膏剂的使用办法:耳穴结合体穴,采用复盖面广,从颈部的哑门、风府、风池。腰部督脉膀胱经腰阳关、关元俞。同时贴敷下肢三阴交及相关反射区。耳穴左右交替使用;需要按疗程方案进行。当症状改善敷贴的时间可以减少,由24小时不间断,到贴12个小时、或者隔天贴、或体穴不用贴只贴耳穴。一般轻度贴一周,中度2-3周。
有益效果:本发明在体表经络部位有关穴位上用药,整个过程治疗安全,无痛苦,无瘢痕,标本兼治,无任何副作用。把经络、神经系统、细胞系统这三大系统管理好,实现调虚实、保证传导功能、提高免疫能力;颈部的血管负责加速血液上注脑,让因缺氧的脑细胞迅速恢复原状,解决脑缺氧导致犯困、疲倦、乏力;同时让病理产物得到清除。
具体实施方式
以下参照具体的实施例来说明本发明。本领域技术人员能够理解,这些实施例仅用于说明本发明,其不以任何方式限制本发明的范围。
实施例1
分别称取草珊瑚提取物100克,远红外陶瓷粉150克、月桂氮酮100克以及热熔胶150克;之后将草珊瑚提取物与月桂氮酮混合均匀,加入热熔胶;加热搅拌,制成稠浸膏状;混入远红外陶瓷粉;混合均匀;得到混合药膏;与纺织布制成5cm×8cm厚为0.5cm的圆形药膏贴。
实施例2
分别称取草珊瑚提取物60克,远红外陶瓷粉90克、月桂氮酮60克以及热熔胶90克;之后将草珊瑚提取物与月桂氮酮混合均匀,加入热熔胶;加热搅拌,制成稠浸膏状;混入远红外陶瓷粉;混合均匀;得到混合药膏;与纺织布制成2.5cm×2.5cm厚为0.5cm的圆形药膏贴。
实施例3
分别称取草珊瑚提取物120克,远红外陶瓷粉180克、月桂氮酮120克以及热熔胶180克;之后将草珊瑚提取物与月桂氮酮混合均匀,加入热熔胶;加热搅拌,制成稠浸膏状;混入远红外陶瓷粉;混合均匀;得到混合药膏;与纺织布制成5cm×8cm厚为0.5cm的圆形药膏贴。
实施例4
分别称取草珊瑚提取物80克,远红外陶瓷粉120克、月桂氮酮80克以及热熔胶120克;之后将草珊瑚提取物与月桂氮酮混合均匀,加入热熔胶;加热搅拌,制成稠浸膏状;混入远红外陶瓷粉;混合均匀;得到混合药膏;与纺织布制成直径2.5cm×2.5cm厚为0.5em的圆形药膏贴。
轻度患者:取上述实施例1药膏贴,敷于颈部的哑门、风府、风池;腰部督脉膀胱经腰阳关、关元俞。同时取上述实施例2药膏贴敷下肢三阴交及相关反射区;耳穴左右交替使用。24小时不间断,贴一周即可。
中度患者:取上述实施例1药膏贴,敷于颈部的哑门、风府、风池;腰部督脉膀胱经腰阳关、关元俞。同时取上述实施例2药膏贴敷下肢三阴交及相关反射区;耳穴左右交替使用。24小时不间断,贴一周:当症状改善敷贴的时间可以减少,体穴不用贴只贴耳穴,续贴一周。
重度患者:取上述实施例3药膏贴,敷于颈部的哑门、风府、风池;腰部督脉膀胱经腰阳关、关元俞。同时取上述实施例4药膏贴敷下肢三阴交及相关反射区;耳穴左右交替使用。24小时不间断,贴两周,观察当症状改善敷贴的时间可以减少,贴12个小时,续贴一周。因重症患者的使用过程需要时间更长,采用“离穴不离经”的原则以保证避免皮肤过敏。
尽管已经示出和描述了本发明的技术方案,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (1)
1.治疗中风后遗症、帕金森及老年痴呆的膏剂,其特征在于:原料按重量百分比组成:草珊瑚提取物20%、远红外陶瓷粉30%、热熔胶30%、月桂氮酮20%;其制备方法,包括如下步骤:(1)草珊瑚提取物与月桂氮酮混合均匀,加入热熔胶;加热搅拌,制成稠浸膏状;(2)按比例混入远红外陶瓷粉;混合均匀;得到混合药膏;(3)与纺织布制成2.5cm×2.5cm或5cm×8cm厚为0.5cm的圆形药膏贴。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810913371.7A CN110812374A (zh) | 2018-08-13 | 2018-08-13 | 治疗中风后遗症、帕金森及老年痴呆的膏剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810913371.7A CN110812374A (zh) | 2018-08-13 | 2018-08-13 | 治疗中风后遗症、帕金森及老年痴呆的膏剂及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110812374A true CN110812374A (zh) | 2020-02-21 |
Family
ID=69546749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810913371.7A Pending CN110812374A (zh) | 2018-08-13 | 2018-08-13 | 治疗中风后遗症、帕金森及老年痴呆的膏剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110812374A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111214595A (zh) * | 2020-02-27 | 2020-06-02 | 郑州爱博尔医疗设备有限公司 | 一种热敷蜡泥块的生产方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104997980A (zh) * | 2015-07-21 | 2015-10-28 | 朱留臣 | 一种用于治疗肩周炎、颈椎病、膝关节增生的中药膏 |
-
2018
- 2018-08-13 CN CN201810913371.7A patent/CN110812374A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104997980A (zh) * | 2015-07-21 | 2015-10-28 | 朱留臣 | 一种用于治疗肩周炎、颈椎病、膝关节增生的中药膏 |
Non-Patent Citations (4)
Title |
---|
冯战: "活血化瘀法治疗中风后遗症疗效观察", 《第二届广西中西医结合心血管病专业、第三届广西中西医结合活血化瘀专业学术研讨会论文集》 * |
孙庆文等: "《贵州中药资源普查重点品种识别手册》", 31 January 2014, 贵州科技出版社 * |
江海林等: "活血化瘀法论治帕金森病", 《中医药临床杂志》 * |
陈少奇等: "石楠藤等7 种活血化瘀中药对老年痴呆模型小鼠记忆力影响的比较研究", 《中国中医药科技》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111214595A (zh) * | 2020-02-27 | 2020-06-02 | 郑州爱博尔医疗设备有限公司 | 一种热敷蜡泥块的生产方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN201640564U (zh) | 一种健康腰带 | |
CN107115519A (zh) | 一种降血压中药外用贴及使用方法 | |
CN110812374A (zh) | 治疗中风后遗症、帕金森及老年痴呆的膏剂及制备方法 | |
CN104224529A (zh) | 艾叶妇科保健贴 | |
CN103565576B (zh) | 隧道式大面积辐射热疗机 | |
CN201642838U (zh) | 温刮温灸罐 | |
CN107693953A (zh) | 一种神经内科治疗装置 | |
CN110507794A (zh) | 一种远红外热敷疗法用中药包 | |
CN201115719Y (zh) | 脐疗温炙器 | |
CN202777037U (zh) | 一种多用途多功能的按摩脚踏板 | |
CN201160937Y (zh) | 治疗颈肩腰腿足痛的远红外热敷垫 | |
CN210447654U (zh) | 一种治疗中风后肩痛的穴位贴 | |
CN207136950U (zh) | 一种粗盐中药热敷固定带 | |
CN207168715U (zh) | 一种红外波联合中草药熏蒸治疗仪 | |
CN109431948A (zh) | 祛除青春痘、淡化痘印、痘疤的中药化妆品及制备方法 | |
CN104432595A (zh) | 仿生保健内衣 | |
CN218652223U (zh) | 用于治疗过敏性鼻炎的中药穴位代温灸敷贴 | |
CN221692472U (zh) | 一种经穴磁疗热疗助眠帽 | |
Wang et al. | Discussion on the Clinical Application of Acupuncture and Moxibustion in TCM Beauty | |
CN103230462A (zh) | 一种理疗透皮吸收治疗各种急慢性疼痛的伤痛酊剂 | |
CN202105225U (zh) | 一种带穴位锥点的温刮温灸罐 | |
Wang et al. | Traditional Chinese Medicine Cupping and Health | |
CN104190004A (zh) | 超声汽浴治疗仪 | |
CN106177231A (zh) | 一种利用五种针法配合中药治疗植物人的方法 | |
Yang | Mechanisms, Contraindication and Therapeutic Effect of Moxibustion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200221 |